osanetant (ACER-801)

News alerts, weekly reports and conference planners

Company:

Sanofi, Zevra Therapeutics

Drug class:

NK-3 antagonist

‹

›

over1year

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause (clinicaltrials.gov)

P1/2, N=49, Completed, Acer Therapeutics Inc. | Phase classification: P2a --> P1/2

over 1 year ago

Phase classification

osanetant (ACER-801)

2years

POSH-MAP: Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov)

P1, N=0, Withdrawn, University of Kansas Medical Center | N=10 --> 0 | Trial completion date: Nov 2025 --> Oct 2023 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2024 --> Sep 2023

2 years ago

Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date

osanetant (ACER-801)

2years

PORT-MAP: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov)

P1, N=1, Terminated, University of Kansas Medical Center | N=10 --> 1 | Trial completion date: Nov 2025 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Nov 2024 --> Sep 2023; Development of the drug program has been discontinued

2 years ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

osanetant (ACER-801)

3years

PORT-MAP: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov)

P1, N=10, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting

3 years ago

Enrollment open

CAST (Calpastatin)

osanetant (ACER-801)

over3years

PORT-MAP: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (clinicaltrials.gov)

P1, N=10, Not yet recruiting, University of Kansas Medical Center

over 3 years ago

New P1 trial

CAST (Calpastatin)

osanetant (ACER-801)